An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines

An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines

Pulmonary fibrosis (PF) is chronic lung disease with only two FDA approved clinically available drugs, with limited safety profile. Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent against TGF-β1-induced in vitro fibrotic events and...

Full description

Bibliographic Details
Main Authors: Swarna Bale, Pooladanda Venkatesh, Manoj Sunkoju, Chandraiah Godugu
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Pharmacology
Subjects:
Withaferin A
pulmonary fibrosis
epithelial to mesenchymal transition
extracellular matrix
inflammation
angiogenesis
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2018.00248/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2018.00248/full

Similar Items